Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia-Reference-Cited by-同舟云学术

Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia

Published:2017-10-31 Issue:12 Volume:92 Page:1356-1361
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Taher Ali T.¹^ORCID,Saliba Antoine N.²,Kuo Kevin H.³^ORCID,Giardina Patricia J.⁴,Cohen Alan R.⁵,Neufeld Ellis J.⁶,Aydinok Yesim⁷,Kwiatkowski Janet L.⁵,Jeglinski Brenda I.⁸,Pietropaolo Keith⁸,Berk Gregory⁸,Viprakasit Vip⁹^ORCID

Affiliation:

1. Department of Internal Medicine; American University of Beirut Medical Center; Beirut Lebanon

2. Department of Medicine; Indiana University School of Medicine; Indianapolis Indiana

3. Division of Medical Oncology and Hematology; University Health Network; Toronto Ontario Canada

4. Weill Medical College of Cornell University; New York New York

5. Division of Hematology, The Children's Hospital of Philadelphia and Perelman School of Medicine of the University of Pennsylvania; Philadelphia Pennsylvania

6. St. Jude Children's Research Hospital; Memphis Tennessee

7. Department of Pediatric Hematology; Ege University Hospital; Izmir Turkey

8. Sideris Pharmaceuticals, Inc.; Lexington Massachusetts

9. Department of Pediatrics & Thalassemia Center; Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok Thailand

Funder

Sideris Pharmaceuticals, Inc

Publisher

Wiley

Subject

Hematology

Reference16 articles.

1. Iron-chelating therapy for transfusional iron overload;Brittenham;N Engl J Med.,2011

2. How I treat transfusional iron overload;Hoffbrand;Blood.,2012

3. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload;Piga;Haematologica.,2006

4. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine;Borgna-Pignatti;Haematologica.,2004

5. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial;Maggio;Blood Cells Mol Dis.,2002

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis regulation through Nrf2 and implications for neurodegenerative diseases;Archives of Toxicology;2024-01-24

2. Understanding the Intricacies of Iron Overload Associated with β-Thalassemia: A Comprehensive Review;Thalassemia Reports;2023-07-03

3. Beta‐thalassaemia major: Prevalence, risk factors and clinical consequences of hypercalciuria;British Journal of Haematology;2022-06-29

4. Iron overload in the HCT patient: a review;Bone Marrow Transplantation;2021-03-29

5. Urinary Metabolic Profile of Patients with Transfusion-Dependent β-Thalassemia Major Undergoing Deferasirox Therapy;Kidney and Blood Pressure Research;2020